Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-World Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Patients Receiving Dupilumab Therapy, With Atopic Dermatitis Control Tool in Gulf Countries

NCT05214326 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05214326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05214326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-World Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Patients Receiving Dupilumab Therapy, With Atopic Dermatitis Control Tool in Gulf Countries
Lead sponsor
Sanofi
Phase
Observational
Overall status
Completed
Start date
January 18, 2022
Completion date
March 21, 2023
Enrollment
187 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis atopic